Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Terminated 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Stomach Neoplasms 1Skin Neoplasms 1Recurrence 1Neoplasm Metastasis 1Glioblastoma 1Gallbladder Neoplasms 1Fanconi Anemia 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 49Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 13Leucovorin 11Irinotecan 11Fluorouracil 11Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × Afatinib × Clear all
NCT06302621 2026-05-15

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Massachusetts General Hospital

Phase 1 Recruiting
70 enrolled
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡